Global Rabies Immune Globulin Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rabies Immune Globulin Market Research Report 2024
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.
According to Mr Accuracy reports new survey, global Rabies Immune Globulin market is projected to reach US$ 694.4 million in 2029, increasing from US$ 424 million in 2022, with the CAGR of 7.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rabies Immune Globulin market research.
The Rabies Immune Globulin market is driven by the critical need to prevent and treat rabies infections effectively. Rabies immune globulin (RIG) is a key component of post-exposure prophylaxis, providing passive immunity against the virus. The increased awareness of rabies' potential severity, particularly in regions with higher prevalence rates, propels market growth. Additionally, the rising number of travelers and potential exposure to rabies in endemic areas contribute to demand. However, challenges include the limited availability of RIG in certain regions and the high cost associated with its production and administration. Ensuring timely access to RIG, especially in remote or resource-constrained areas, and addressing potential allergic reactions or adverse events are ongoing concerns. The market's success depends on the collaboration between healthcare systems and regulatory bodies to ensure sufficient availability, proper distribution, and affordability of rabies immune globulin, ultimately reducing the global burden of this deadly disease.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rabies Immune Globulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS
Segment by Type
ERIG
HRIG
Category II Exposure
Category III Exposure
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Rabies Immune Globulin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Rabies Immune Globulin market is projected to reach US$ 694.4 million in 2029, increasing from US$ 424 million in 2022, with the CAGR of 7.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rabies Immune Globulin market research.
The Rabies Immune Globulin market is driven by the critical need to prevent and treat rabies infections effectively. Rabies immune globulin (RIG) is a key component of post-exposure prophylaxis, providing passive immunity against the virus. The increased awareness of rabies' potential severity, particularly in regions with higher prevalence rates, propels market growth. Additionally, the rising number of travelers and potential exposure to rabies in endemic areas contribute to demand. However, challenges include the limited availability of RIG in certain regions and the high cost associated with its production and administration. Ensuring timely access to RIG, especially in remote or resource-constrained areas, and addressing potential allergic reactions or adverse events are ongoing concerns. The market's success depends on the collaboration between healthcare systems and regulatory bodies to ensure sufficient availability, proper distribution, and affordability of rabies immune globulin, ultimately reducing the global burden of this deadly disease.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rabies Immune Globulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS
Segment by Type
ERIG
HRIG
Segment by Application
Category II Exposure
Category III Exposure
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Rabies Immune Globulin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices